Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
Antibody levels remained well above baseline across all six serotypes and age…
Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference
Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference…
Indian MedTech Company Makes a Global Mark at PCR London Valves 2025
Presents One-Year Outcomes from the LANDMARK Randomized Controlled TrialVAPI, India, Nov. 25,…
The Volpi Rosse Menarini: The ‘Fantastic Ten’ are ready for the 2025 – 2026 Season
Italian wheelchair basketball team, sponsored by Menarini, was presented to the press…
Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
Positive results from ianalumab pivotal Phase III trial in ITP patients previously…
Press Release: Sanofi and Regenerons Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the…
Menarini Group Announces New Data on ELZONRIS (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
Data spans five abstracts including two oral presentations with important findings for…
Alzheimer’s Association Statement on Oral Semaglutide Phase 3 Topline Data Release
- Results Underscore Need for Continued Research and Diverse Treatment PipelineCHICAGO, Nov.…
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc.…
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its…